GO
Loading...

Vertex Pharmaceuticals Inc

More

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • UPDATE 2-Vertex posts loss as hepatitis drug sales fall Thursday, 1 Nov 2012 | 10:52 PM ET

    Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • *3rd quarter net loss 27 cents a share. Nov 1- Vertex Pharmaceuticals Inc reported a net loss for the third quarter on Thursday with results hurt by fast-declining sales of its Incivek hepatitis C drug, as the company turned its attention to developing a next generation of treatments for the serious liver disease.

  • --Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.

  • --Acorda Therapeutics Inc: rescheduled third-quarter financial results and conference call to Oct. 31 from Oct. 30. --Advent Software Inc reschedules third-quarter results and conference call to Oct. 30. --AGCO Corp rescheduled third-quarter results to Oct 31, 8 am Eastern Time from Oct. 30.

  • --Martha Stewart Living Omnimedia Inc rescheduled third-quarter results to Nov. 1 from Oct. 30. --Vertex Pharmaceuticals Inc rescheduled third-quarter 2012 earnings and conference call to after markets close on Nov. 1 from Oct. 29. --The McGraw-Hill Companies Inc rescheduled third-quarter earnings and conference call to Nov. 2 from Oct. 31.

  • Abbott Labs rises on hepatitis C drug data Monday, 15 Oct 2012 | 11:48 AM ET

    NEW YORK-- Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease. Abbott shares rose $2.77, or 4 percent, to close at $72.05 Monday.

  • Oct 11- Vertex Pharmaceuticals Inc:. *Data from phase 2 combination study of vx-809 and ivacaftor in people with. cystic fibrosis who have the most common genetic mutation presented.

  • Stocks to Watch: JNJ, LLY, EW & More Tuesday, 9 Oct 2012 | 8:08 AM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Tuesdays morning movers.

  • Oct 2- Vertex Pharmaceuticals Inc:. *Lazard raises Vertex Pharmaceuticals Inc price target to $75 from. Reuters Station users, click. 1568.

  • Bristol’s Hep C Drug Blowup May Benefit These Stocks Thursday, 2 Aug 2012 | 10:51 AM ET
    bristol_myers_squibb.jpg

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • Stocks to Watch: BBY, HMA, THC & More Thursday, 28 Jun 2012 | 1:37 PM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Thursday's midday movers:

  • Cramer makes the call on viewers' favorite stocks.

  • Stocks End Higher, but Spain Weighs; FB Sags 9% Tuesday, 29 May 2012 | 4:45 PM ET

    Stocks rallied more than 1 percent across the board Tuesday to close near session highs, but the euro remained near its lowest level against the dollar since July 2010 amid renewed jitters over Spain.

  • Stocks to Watch: CHK, FB, VRTX & More Tuesday, 29 May 2012 | 2:47 PM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Tuesday's midday movers:

  • Stocks to Watch: JCP, VRTX, CHK, FB & More Tuesday, 29 May 2012 | 7:53 AM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Tuesday’s morning movers:

  • Cramer makes the call on viewers' favorite stocks.

  • Stocks Off Lows, but Dow Logs 4-Day Decline Monday, 7 May 2012 | 4:48 PM ET

    Stocks finished mixed Monday, recovering from their session lows, as investors shrugged off worries over the eurozone's ability to handle its sovereign debt woes following France and Greece's elections.

  • Stocks to Watch: TSN, GOOG, SIRI & More Monday, 7 May 2012 | 7:52 AM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Monday's morning movers:

  • Vertex Hopes Two Cystic Fibrosis Drugs Better Than One Tuesday, 24 Apr 2012 | 12:00 PM ET

    Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.